Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary... see more

Recent & Breaking News (NDAQ:FBIO)

Fortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights

GlobeNewswire May 10, 2017

BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience

GlobeNewswire May 10, 2017

Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis

GlobeNewswire May 4, 2017

Fortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

GlobeNewswire April 27, 2017

Checkpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

GlobeNewswire April 27, 2017

Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer

GlobeNewswire April 24, 2017

Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis

GlobeNewswire April 5, 2017

Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs

GlobeNewswire April 4, 2017

Fortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference

GlobeNewswire March 30, 2017

Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

GlobeNewswire March 20, 2017

Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016

GlobeNewswire March 16, 2017

Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders

GlobeNewswire March 14, 2017

Fortress Biotech to Present at the 29th Annual ROTH Conference

GlobeNewswire March 9, 2017

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

GlobeNewswire February 28, 2017

Fortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing

GlobeNewswire February 2, 2017

National Holdings’ OPN Capital Markets Closes $94.5 Million Private Placement Financing for Mustang Bio, Inc., a Subsidiary of Fortress Biotech

GlobeNewswire February 2, 2017

Fortress Biotech Forms New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for AL Amyloidosis

GlobeNewswire January 4, 2017

Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

GlobeNewswire January 3, 2017

Mid-Afternoon Market Update: Gold Futures Up 1.5%; Endologix Shares Spike Higher

Benzinga.com  December 29, 2016

12 Biggest Mid-Day Gainers For Thursday

Benzinga.com  December 29, 2016